Global Histone Methyltransferases Market Overview
Chem Reports estimates that the global Histone Methyltransferases Market was valued at USD XXXX million in 2024 and is expected to reach USD XXXX million by 2035, growing at a CAGR of XX% during the forecast period 2025–2035.
Histone methyltransferases (HMTs) are critical epigenetic enzymes responsible for catalyzing the methylation of histone proteins, thereby regulating gene expression without altering DNA sequence. Dysregulation of these enzymes is strongly associated with oncogenesis, tumor progression, and resistance mechanisms across multiple cancer types. As a result, histone methyltransferases have emerged as high-value therapeutic targets in oncology and precision medicine.
Market growth is primarily driven by rapid advances in epigenetics research, increasing oncology drug pipelines targeting chromatin-modifying enzymes, rising prevalence of cancer globally, and expanding investments in translational and precision medicine. Pharmaceutical companies and biotech firms are increasingly focusing on selective HMT inhibitors and companion diagnostics, strengthening long-term market potential.
Impact of COVID-19 on the Histone Methyltransferases Market
The COVID-19 pandemic had a short-term negative impact on the Histone Methyltransferases Market in 2020. Temporary disruptions in laboratory research, clinical trial delays, and reallocation of healthcare funding toward pandemic management slowed early-stage epigenetic research activities. However, post-pandemic recovery has been strong, supported by resumed oncology trials, increased biotech funding, and renewed emphasis on innovative cancer therapeutics. The market has since regained momentum, with epigenetic drug discovery returning to pre-pandemic growth trajectories.
Global Histone Methyltransferases Market Segmentation
By Type
EZ (Enhancer of Zeste)
The EZ family, particularly EZH2, represents the largest and most commercially advanced segment due to its strong association with multiple cancers, including lymphomas and solid tumors. EZ inhibitors have progressed significantly in clinical development.
SET1
SET1 methyltransferases are involved in transcriptional activation and chromatin organization. This segment is primarily driven by academic research and early-stage drug discovery programs.
SET2
SET2 enzymes play a role in transcription elongation and genome stability. Interest in this segment is growing due to its relevance in DNA damage response and cancer biology.
SMYD
SMYD family enzymes are increasingly studied for their role in tumor proliferation and cardiovascular diseases. This segment is gaining traction in exploratory oncology research.
SUV39
SUV39 methyltransferases are associated with heterochromatin formation and gene silencing. Research demand is supported by their involvement in cancer progression and epigenetic regulation.
SUV4-20
SUV4-20 enzymes regulate chromatin compaction and genome integrity. This segment remains niche but relevant for advanced epigenetics research.
RIZ
RIZ methyltransferases are linked to tumor suppressor activity. Market demand is largely research-oriented with emerging therapeutic interest.
By Application
Lung Cancer
Lung cancer represents a major application segment, driven by high disease prevalence and increasing research into epigenetic drivers of tumor resistance and metastasis.
Liver Cancer
Rising incidence of hepatocellular carcinoma globally supports growing demand for novel epigenetic targets, including histone methyltransferases.
Breast Cancer
Breast cancer applications are expanding due to strong links between HMT dysregulation and hormone-resistant tumor subtypes.
Other Applications
Includes hematological malignancies, prostate cancer, colorectal cancer, and rare cancers, where epigenetic therapies are increasingly explored.
Key Players in the Global Histone Methyltransferases Market
The Histone Methyltransferases Market is highly innovation-driven, comprising pharmaceutical companies, specialized biotech firms, and research-focused solution providers.
Competitive Outlook
Competition in the market is driven by pipeline depth, target selectivity, clinical progression, and strategic partnerships. Companies with advanced EZH2 and SET-domain inhibitor programs, strong IP portfolios, and companion diagnostic capabilities are expected to maintain competitive leadership.
Regional Analysis
North America
North America dominates the market due to advanced biotechnology infrastructure, strong pharmaceutical R&D investment, high cancer incidence, and the presence of leading epigenetics-focused companies. The United States accounts for the majority of regional demand.
Europe
Europe represents a strong research-driven market, supported by government-funded biomedical research programs, established oncology pipelines, and active clinical trial activity in epigenetic therapies.
Asia-Pacific
Asia-Pacific is the fastest-growing region, driven by expanding biotech ecosystems, rising cancer prevalence, increasing clinical research outsourcing, and growing investments in precision medicine across China, Japan, South Korea, and India.
South America
South America shows moderate growth, supported by improving cancer diagnosis rates and gradual expansion of pharmaceutical research capabilities.
Middle East & Africa
The Middle East & Africa market is emerging, driven by increasing healthcare investment, rising cancer awareness, and selective adoption of advanced oncology diagnostics and therapeutics.
DRTO Analysis (Drivers, Restraints, Trends & Opportunities)
Drivers
Restraints
Trends
Opportunities
SWOT Analysis
Strengths
Weaknesses
Opportunities
Threats
Porter’s Five Forces Analysis
1. Threat of New Entrants – Low
2. Bargaining Power of Suppliers – Low
3. Bargaining Power of Buyers – High (Post-Approval)
4. Threat of Substitutes – Moderate
5. Competitive Rivalry – High
Competitive Landscape Matrix
|
Company |
Core Focus |
Pipeline Strength |
Geographic Reach |
Competitive Position |
|
Epizyme Inc. |
EZH2 inhibitors |
Very High |
Global |
Market Pioneer |
|
Constellation Pharmaceuticals |
Chromatin targets |
High |
North America |
Innovation Leader |
|
Cellcentric Ltd. |
Transcriptional regulation |
High |
Europe / Global |
Oncology Specialist |
|
Pfizer |
Oncology platforms |
Very High |
Global |
Big-Pharma Integrator |
|
GlaxoSmithKline |
Epigenetics & oncology |
High |
Global |
Strategic Investor |
|
Eisai Co. Ltd. |
Precision oncology |
Medium |
Asia / Global |
Regional Innovator |
|
Reaction Biology Corp. |
Assay & screening |
Medium |
Global |
R&D Enabler |
|
Sigma-Aldrich |
Research tools |
Medium |
Global |
Research Backbone |
Investor-Focused Executive Summary
The Histone Methyltransferases Market represents a high-value, innovation-driven segment within the global epigenetics and oncology landscape. Growth is fueled by the convergence of precision medicine, rising cancer burden, and mechanistically targeted drug development.
While the market is characterized by long development cycles and elevated clinical risk, it offers significant upside potential through first-in-class and best-in-class therapies—particularly in EZH2 and SET-domain targets. Strategic acquisitions and licensing by large pharmaceutical companies validate the long-term commercial potential of this space.
Key investment highlights:
Overall, the Histone Methyltransferases Market is best suited for long-term, risk-tolerant investors seeking exposure to cutting-edge epigenetic therapeutics with transformational clinical and commercial potential.
1. Market Overview of Histone Methyltransferases
1.1 Histone Methyltransferases Market Overview
1.1.1 Histone Methyltransferases Product Scope
1.1.2 Market Status and Outlook
1.2 Histone Methyltransferases Market Size by Regions:
1.3 Histone Methyltransferases Historic Market Size by Regions
1.4 Histone Methyltransferases Forecasted Market Size by Regions
1.5 Covid-19 Impact on Key Regions, Keyword Market Size YoY Growth
1.5.1 North America
1.5.2 East Asia
1.5.3 Europe
1.5.4 South Asia
1.5.5 Southeast Asia
1.5.6 Middle East
1.5.7 Africa
1.5.8 Oceania
1.5.9 South America
1.5.10 Rest of the World
1.6 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
1.6.1 Covid-19 Impact: Global GDP Growth, Projections
1.6.2 Covid-19 Impact: Commodity Prices Indices
1.6.3 Covid-19 Impact: Global Major Government Policy
2. Covid-19 Impact Histone Methyltransferases Sales Market by Type
2.1 Global Histone Methyltransferases Historic Market Size by Type
2.2 Global Histone Methyltransferases Forecasted Market Size by Type
2.3 EZ
2.4 SET1
2.5 SET2
2.6 SMYD
2.7 SUV39
2.8 SUV4-20
2.9 RIZ
3. Covid-19 Impact Histone Methyltransferases Sales Market by Application
3.1 Global Histone Methyltransferases Historic Market Size by Application
3.2 Global Histone Methyltransferases Forecasted Market Size by Application
3.3 Lung Cancer
3.4 Liver Cancer
3.5 Breast Cancer
3.6 Others
4. Covid-19 Impact Market Competition by Manufacturers
4.1 Global Histone Methyltransferases Production Capacity Market Share by Manufacturers
4.2 Global Histone Methyltransferases Revenue Market Share by Manufacturers
4.3 Global Histone Methyltransferases Average Price by Manufacturers
5. Company Profiles and Key Figures in Histone Methyltransferases Business
5.1 Cellcentric Ltd.
5.1.1 Cellcentric Ltd. Company Profile
5.1.2 Cellcentric Ltd. Histone Methyltransferases Product Specification
5.1.3 Cellcentric Ltd. Histone Methyltransferases Production Capacity, Revenue, Price and Gross Margin
5.2 Constellation Pharmaceuticals
5.2.1 Constellation Pharmaceuticals Company Profile
5.2.2 Constellation Pharmaceuticals Histone Methyltransferases Product Specification
5.2.3 Constellation Pharmaceuticals Histone Methyltransferases Production Capacity, Revenue, Price and Gross Margin
5.3 Domainex
5.3.1 Domainex Company Profile
5.3.2 Domainex Histone Methyltransferases Product Specification
5.3.3 Domainex Histone Methyltransferases Production Capacity, Revenue, Price and Gross Margin
5.4 Sequenom Inc.
5.4.1 Sequenom Inc. Company Profile
5.4.2 Sequenom Inc. Histone Methyltransferases Product Specification
5.4.3 Sequenom Inc. Histone Methyltransferases Production Capacity, Revenue, Price and Gross Margin
5.5 Ribomed Biotechnologies Inc.
5.5.1 Ribomed Biotechnologies Inc. Company Profile
5.5.2 Ribomed Biotechnologies Inc. Histone Methyltransferases Product Specification
5.5.3 Ribomed Biotechnologies Inc. Histone Methyltransferases Production Capacity, Revenue, Price and Gross Margin
5.6 Reaction Biology Corp.
5.6.1 Reaction Biology Corp. Company Profile
5.6.2 Reaction Biology Corp. Histone Methyltransferases Product Specification
5.6.3 Reaction Biology Corp. Histone Methyltransferases Production Capacity, Revenue, Price and Gross Margin
5.7 Sigma-Aldrich
5.7.1 Sigma-Aldrich Company Profile
5.7.2 Sigma-Aldrich Histone Methyltransferases Product Specification
5.7.3 Sigma-Aldrich Histone Methyltransferases Production Capacity, Revenue, Price and Gross Margin
5.8 Epitherapeutics APS
5.8.1 Epitherapeutics APS Company Profile
5.8.2 Epitherapeutics APS Histone Methyltransferases Product Specification
5.8.3 Epitherapeutics APS Histone Methyltransferases Production Capacity, Revenue, Price and Gross Margin
5.9 Pharmacyclics Inc
5.9.1 Pharmacyclics Inc Company Profile
5.9.2 Pharmacyclics Inc Histone Methyltransferases Product Specification
5.9.3 Pharmacyclics Inc Histone Methyltransferases Production Capacity, Revenue, Price and Gross Margin
5.10 Epizyme Inc.
5.10.1 Epizyme Inc. Company Profile
5.10.2 Epizyme Inc. Histone Methyltransferases Product Specification
5.10.3 Epizyme Inc. Histone Methyltransferases Production Capacity, Revenue, Price and Gross Margin
5.11 Sirtris
5.11.1 Sirtris Company Profile
5.11.2 Sirtris Histone Methyltransferases Product Specification
5.11.3 Sirtris Histone Methyltransferases Production Capacity, Revenue, Price and Gross Margin
5.12 Eisai Co. Ltd.
5.12.1 Eisai Co. Ltd. Company Profile
5.12.2 Eisai Co. Ltd. Histone Methyltransferases Product Specification
5.12.3 Eisai Co. Ltd. Histone Methyltransferases Production Capacity, Revenue, Price and Gross Margin
5.13 Glaxosmithkline (Gsk)
5.13.1 Glaxosmithkline (Gsk) Company Profile
5.13.2 Glaxosmithkline (Gsk) Histone Methyltransferases Product Specification
5.13.3 Glaxosmithkline (Gsk) Histone Methyltransferases Production Capacity, Revenue, Price and Gross Margin
5.14 Pfizer
5.14.1 Pfizer Company Profile
5.14.2 Pfizer Histone Methyltransferases Product Specification
5.14.3 Pfizer Histone Methyltransferases Production Capacity, Revenue, Price and Gross Margin
5.15 Prognosdx Health Inc.
5.15.1 Prognosdx Health Inc. Company Profile
5.15.2 Prognosdx Health Inc. Histone Methyltransferases Product Specification
5.15.3 Prognosdx Health Inc. Histone Methyltransferases Production Capacity, Revenue, Price and Gross Margin
5.16 Rana Therapeutics Inc.
5.16.1 Rana Therapeutics Inc. Company Profile
5.16.2 Rana Therapeutics Inc. Histone Methyltransferases Product Specification
5.16.3 Rana Therapeutics Inc. Histone Methyltransferases Production Capacity, Revenue, Price and Gross Margin
6. North America
6.1 North America Histone Methyltransferases Market Size
6.2 North America Histone Methyltransferases Key Players in North America
6.3 North America Histone Methyltransferases Market Size by Type
6.4 North America Histone Methyltransferases Market Size by Application
7. East Asia
7.1 East Asia Histone Methyltransferases Market Size
7.2 East Asia Histone Methyltransferases Key Players in North America
7.3 East Asia Histone Methyltransferases Market Size by Type
7.4 East Asia Histone Methyltransferases Market Size by Application
8. Europe
8.1 Europe Histone Methyltransferases Market Size
8.2 Europe Histone Methyltransferases Key Players in North America
8.3 Europe Histone Methyltransferases Market Size by Type
8.4 Europe Histone Methyltransferases Market Size by Application
9. South Asia
9.1 South Asia Histone Methyltransferases Market Size
9.2 South Asia Histone Methyltransferases Key Players in North America
9.3 South Asia Histone Methyltransferases Market Size by Type
9.4 South Asia Histone Methyltransferases Market Size by Application
10. Southeast Asia
10.1 Southeast Asia Histone Methyltransferases Market Size
10.2 Southeast Asia Histone Methyltransferases Key Players in North America
10.3 Southeast Asia Histone Methyltransferases Market Size by Type
10.4 Southeast Asia Histone Methyltransferases Market Size by Application
11. Middle East
11.1 Middle East Histone Methyltransferases Market Size
11.2 Middle East Histone Methyltransferases Key Players in North America
11.3 Middle East Histone Methyltransferases Market Size by Type
11.4 Middle East Histone Methyltransferases Market Size by Application
12. Africa
12.1 Africa Histone Methyltransferases Market Size
12.2 Africa Histone Methyltransferases Key Players in North America
12.3 Africa Histone Methyltransferases Market Size by Type
12.4 Africa Histone Methyltransferases Market Size by Application
13. Oceania
13.1 Oceania Histone Methyltransferases Market Size
13.2 Oceania Histone Methyltransferases Key Players in North America
13.3 Oceania Histone Methyltransferases Market Size by Type
13.4 Oceania Histone Methyltransferases Market Size by Application
14. South America
14.1 South America Histone Methyltransferases Market Size
14.2 South America Histone Methyltransferases Key Players in North America
14.3 South America Histone Methyltransferases Market Size by Type
14.4 South America Histone Methyltransferases Market Size by Application
15. Rest of the World
15.1 Rest of the World Histone Methyltransferases Market Size
15.2 Rest of the World Histone Methyltransferases Key Players in North America
15.3 Rest of the World Histone Methyltransferases Market Size by Type
15.4 Rest of the World Histone Methyltransferases Market Size by Application
16 Histone Methyltransferases Market Dynamics
16.1 Covid-19 Impact Market Top Trends
16.2 Covid-19 Impact Market Drivers
16.3 Covid-19 Impact Market Challenges
16.4 Porter?s Five Forces Analysis
18 Regulatory Information
17 Analyst's Viewpoints/Conclusions
18 Appendix
18.1 Research Methodology
18.1.1 Methodology/Research Approach
18.1.2 Data Source
18.2 Disclaimer
Global Histone Methyltransferases Market Segmentation
By Type
EZ (Enhancer of Zeste)
The EZ family, particularly EZH2, represents the largest and most commercially advanced segment due to its strong association with multiple cancers, including lymphomas and solid tumors. EZ inhibitors have progressed significantly in clinical development.
SET1
SET1 methyltransferases are involved in transcriptional activation and chromatin organization. This segment is primarily driven by academic research and early-stage drug discovery programs.
SET2
SET2 enzymes play a role in transcription elongation and genome stability. Interest in this segment is growing due to its relevance in DNA damage response and cancer biology.
SMYD
SMYD family enzymes are increasingly studied for their role in tumor proliferation and cardiovascular diseases. This segment is gaining traction in exploratory oncology research.
SUV39
SUV39 methyltransferases are associated with heterochromatin formation and gene silencing. Research demand is supported by their involvement in cancer progression and epigenetic regulation.
SUV4-20
SUV4-20 enzymes regulate chromatin compaction and genome integrity. This segment remains niche but relevant for advanced epigenetics research.
RIZ
RIZ methyltransferases are linked to tumor suppressor activity. Market demand is largely research-oriented with emerging therapeutic interest.
By Application
Lung Cancer
Lung cancer represents a major application segment, driven by high disease prevalence and increasing research into epigenetic drivers of tumor resistance and metastasis.
Liver Cancer
Rising incidence of hepatocellular carcinoma globally supports growing demand for novel epigenetic targets, including histone methyltransferases.
Breast Cancer
Breast cancer applications are expanding due to strong links between HMT dysregulation and hormone-resistant tumor subtypes.
Other Applications
Includes hematological malignancies, prostate cancer, colorectal cancer, and rare cancers, where epigenetic therapies are increasingly explored.
Key Players in the Global Histone Methyltransferases Market
The Histone Methyltransferases Market is highly innovation-driven, comprising pharmaceutical companies, specialized biotech firms, and research-focused solution providers.
Competitive Outlook
Competition in the market is driven by pipeline depth, target selectivity, clinical progression, and strategic partnerships. Companies with advanced EZH2 and SET-domain inhibitor programs, strong IP portfolios, and companion diagnostic capabilities are expected to maintain competitive leadership.
Upto 24 to 48 hrs (Working Hours)
Upto 72 hrs max (Working Hours) - Weekends and Public Holidays
Single User License - Allows access to only one person to the report.
Multi User License - Allows sharing with max 5 persons within organization.
Corporate License – Can be shared across entire organization.
Online Payments with PayPal
Wire Transfer / Bank Transfer
At ChemReports, we understand that business decisions can’t wait. Our research specialists are available anytime to answer your queries and guide you through our reports, ensuring quick and reliable assistance.
ChemReports provides 360° market analysis across materials, technologies, and global chemical sectors—helping you make confident business decisions.
We turn complex data into strategic insights to support fact-based decisions, market entry strategies, and competitive analysis.
Your personal and business information is completely secure with us. We value your trust and ensure strict confidentiality.
Need tailored insights? Our analysts provide custom reports built on authentic data and aligned with your specific business goals.